Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (4) : 480-484     DOI: 10.1007/s11684-009-0083-9
Research articles |
Effect of compound Sophorae Flavescentis Jiechangrong capsule on expression of NF-κB p65 and STAT6 in the intestinal mucosa of patients with ulcerative colitis
Heng FAN MD,Jia ZHAO MM,Lin SHEN BM,Qing TANG MD,Zhexin SHOU MM,Li LIANG BM,Yi LIAO BM,Xiaoyan CHEN BM,
Department of Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China;
Download: PDF(205 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  The effects of compound Sophorae Flavescentis Jiechangrong capsule (CSFJC) on the expression of nuclear factor-κB p65 (NF-κB p65) and signal transducer and activator of transcription 6 (STAT6) in the intestinal mucosa of patients with ulcerative colitis and the possible mechanism were investigated. Eighteen patients with ulcerative colitis were randomly divided into a traditional Chinese medicine (TCM) group (n = 11) treated by CSFJC and a western medicine (WM) group (n = 7) treated by Sulfasalazine tablets. The treatment duration lasted eight weeks. Before and after the treatment, the symptoms and the physical signs were observed, and the routine stool test, the colonoscopy, and pathological examination were performed in the two groups. The expression levels of NF-κBp65 and STAT6 were detected by using immunohistochemistry. The results showed that the total effective rate of the curative effectiveness in TCM and WM groups was 100% and 71.4%, respectively, and the total effective rate of colonic mucosa lesion in TCM and WM groups was 90.9% and 71.4%, respectively, with the differences being significant (all P < 0.05). The total effective rate of syndromes of damp-heat blocking according to the TCM in TCM and WM groups was 90.9% and 71.4%, respectively. After the treatment, the expression of NF-κB p65 and STAT6 in the two groups was decreased, and the decrease of NF-κB p65 and STAT6 expression in TCM group was more significant than in WM group (P < 0.05). It was concluded that CSFJC can inhibit the activation and expression of NF-κB p65 and STAT6 in the intestinal mucosa of patients with ulcerative colitis, which is a possible mechanism for CSFJC treating ulcerative colitis.
Keywords colitis, ulcerative      compound Sophorae Flavescentis Jiechangrong capsule      nuclear factor-κB p65 (NF-κB p65)      signal transducer and activator of transcription 6 (STAT6)      
Issue Date: 05 December 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0083-9     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I4/480
Ye R G, Lu Z Y. Internal Medicine. 6th ed. Beijing: People’s Health Press, 2004, 406―407(in Chinese)
Fan H, Shou Z X, Lv J F, Shen L, Yang S L, Chen R. 11cases of treatment of ulcerative colitis with Compound Sophorae FlavescentisJiechangrong capsule. Zhong Guo Zhong XiYi Jie He Za Zhi, 2007, 15(1): 60―61 (in Chinese)
Zhou J P, Deng C S. Effect of Rosiglitazone onexpression of NF-κB and ICAM-1 in the intestinal musoca of ratswith ulcerative colitis. Shi Jie Hua RenXiao Hua Za Zhi, 2006, 14(1): 104―108 (in Chinese)
Gan H T, Chen Y Q, Ouyang Q. Sulfasalazine inhibits activation of nuclear factor-κBin patients with ulcerative colitis. JGastroenterol Hepatol, 2005, 20(7): 1016―1024
Huang W C, Chen J J, Chen C C. c-Src-dependent tyrosine phosphorylation of IKKbeta isinvolved in tumor necrosis factor-alpha-induced intercellular adhesionmolecule-1 expression. J Biol Chem, 2003, 278(11): 9944―9952

doi: 10.1074/jbc.M208521200
Verma I M, Stevenson J K, Schwarz E M, Van Antwerp D, Miyamoto S. Rel/NF-κB/IκBfamily: Intimate tales of association and dissociation. Genes Dev, 1995, 9(22): 2723―2735

doi: 10.1101/gad.9.22.2723
Ponnappan S, Cullen S J, Ponnappan U. Constitutive degradation of I kappa B alpha in humanTlymphocytes is mediated by calpain. ImmunAgeing, 2005, 2: 15

doi: 10.1186/1742-4933-2-15
Baldwin A S Jr. The NF-κB and IκB proteins: New discoveries and insights. Annu Rel Immunol, 1996, 14: 649―683

doi: 10.1146/annurev.immunol.14.1.649
Bruns H A, Kaplan M H. The role of constitutivelyactive Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol, 2006, 57(3): 245―253

doi: 10.1016/j.critrevonc.2005.08.005
Kraus J, Borner C, Hollt V. Distinct palindromic extensions of the 5’-TTC…GAA-3’motif allow STAT6 binding in vivo. FASEBJ , 2003, 17(2): 304―306
Fan H, Chen R, Shen L, Lv J F, Xiong P C, Shou Z X, Zhuang X. Oxymatrine Improves TNBS-inducedColitis in Rats by Inhibiting the Expression of NF-κB p65. J Huazhong Univ Sci Technol (Med Sci), 2008, 28(4): 415―420
Fan H, Duan X Y, Zhuang X, Lv J F, Shou Z X. Effect of Wumeiwan on NF-κBp65in colon tissue of rats with ulcerative colitis. Shi Jie Hua Ren Xiao Hua Za Zhi, 2008, 16(8): 896―899 (in Chinese)
Baeuerle P A, Baltimore D. NF-κB: ten years after. Cell, 1996, 87(1): 13―20

doi: 10.1016/S0092-8674(00)81318-5
Baeuerle P A, Henkel T. Function and activation ofNF-kappa B in the immune system. Annu RevImmunol, 1994, 12: 141―179
Lv J F, Fan H, Shen L, Shou Z X, Zhuang X. Effects of Oxymatrine injection on expressionof cytokines and nuclear factor-κB p65 in colonic intestinalmucosa of rats with experimental colitis. Shi Jie Hua Ren Xiao Hua Za Zhi, 2008, 16(20): 2289―2294 (in Chinese)
Gan H T, Ou Y Q, Chen Y Q, Xia Q J. Activationof nuclear factor-κB and effects of anti-inflammatory treatmentthereon in intestinal mucosa of patients with ulcerative colitis. Zhong Hua Yi Xue Za Zhi, 2002, 82(6): 384―388 (in Chinese)
Pang Y H, Zheng C Q, Ling B, Hu G Z, Zhang W J. The expression of signal transducer andactivator of transcription 6 in the ulcerative colitis. Shi Jie Hua Ren Xiao Hua Za Zhi, 2004, 12(10): 2484―2486 (in Chinese)
Andresen L, Jørgensen V L, Perner A, Hansen A, Eugen-Olsen J, Rask-Madsen J. Activation of nuclear factor κB in colonic mucosafrom patients with collagenous and ulcerative colitis. Gut, 2005, 54(4): 503―509

doi: 10.1136/gut.2003.034165
Hanauer S B. Medical therapy for ulcerative colitis 2004. Gastroenterology, 2004, 126(6): 1582―1592

doi: 10.1053/j.gastro.2004.02.071
Abreu M T, Vora P, Faure E, Thomas L S, Arnold E T, Arditi M. Decreased expression of Toll-like receptor-4 and MD-2correlates with intestinal epithelial cell protection against dysregulatedpro inflammatory gene expression in response to bacterial lipopolysaccharide. J immunol, 2001, 167(3): 1609―1616
Mitsuyama K, Suzuki A, Tomiyasu N, Takaki K, Toyonaga A, Sata M. Transcription factor-targeted therapies in inflammatorybowel disease. Digestion, 2001, 63(suppl 1): 68―72

doi: 10.1159/000051914
Moynagh P N. The NF-κB pathway. J Cell Sci, 2005, 118(pt20): 4589―4592

doi: 10.1242/jcs.02579
Fan H, Qiu M Y, Mei J J, Shen G X, Liu S L, Chen R. Effectsof four regulating intestines prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis. World J Gastroenterol, 2005, 11(31): 4800―4806
Fan H, Shen L, Tang Q, Xiong P C, Shou Z X, Liao Y, Liang L, Chen X Y. Effect of Wumeiwan on cytokines TNF-α, IL-6, IL-8,IL-10 and expression of NF-kB p65 in rats with ulceratine colitis. J Huazhong Uni Sci Technol (Med Sci), 2009; 29(5): 650–654
Zhu J, Guo L, Watson C J, Hu-Li J, Paul W E. Stat6 is necessary and sufficient forIL-4’s role in Th2 differentiation and cell expansion. J Immunol, 2001; 166(12): 7276―7281
[1] Rui ZHU MD, Heng FAN MD, Lin SHEN MD, Jianguo LIU BD, Jia ZHAO MM, . Expression of STAT6 and NF-κB p65 in the colon mucosa of patients with ulcerative colitis[J]. Front. Med., 2009, 3(4): 475-479.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed